That section, Paragraph 3d, specified that this sort of innovations are patentable only if "they differ substantially in Qualities regarding efficacy."[136][139] At just one stage, Novartis went to court docket to test to invalidate Paragraph 3d; it argued that the provision was unconstitutionally obscure Which it violated Journeys. Novartis lost http://emiliocoqfi.newbigblog.com/16803795/an-unbiased-view-of-novatis-paris